{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-097582","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.582309+00:00","generated_at":"2026-05-15T17:44:46.503758+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corbus Q4 net loss $20.6M; cash $163.3M into 2028; key CRB-701/913 catalysts mid-2026","bullets":["Q4 2025 net loss $20.6M ($1.25/share) vs $9.5M ($0.78) in Q4 2024; operating expenses rose to $22.0M.","Cash $163.3M at Dec 31, 2025; extended runway into 2028 after $75M public offering in Q4.","CRB-701 Phase 1/2 unconfirmed ORR: HNSCC 47.6%, cervical 37.5%; monotherapy data and FDA protocol discussions expected mid-2026.","CRB-913 Phase 1a: 2.9% placebo-adjusted weight loss at 14 days; Phase 1b CANYON-1 (n=240) results due summer 2026.","CRB-601 deprioritized; no further patient enrollment. Pipeline updates from ESMO 2025 and SITC 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-097582","json":"https://secwatch.observer/filing/0001193125-26-097582.json","markdown":"https://secwatch.observer/filing/0001193125-26-097582.md","text":"https://secwatch.observer/filing/0001193125-26-097582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526097582/0001193125-26-097582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526097582/crbp-20260309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:44:46.503758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"372b362c4e3304372dd0d5ecdffd45fefad2ac07","claim":"Corbus Pharmaceuticals Holdings, Inc. reported fourth quarter and year ended December 31, 2025 results: net income net loss of approximately $20.6 million, or a net loss per basic and diluted share of $1.25, EPS net loss per basic and diluted share of $1.25.","evidence_excerpt":"The Company reported a net loss of approximately $20.6 million, or a net loss per basic and diluted share of $1.25, for the three months ended December 31, 2025, compared to a net loss of $9.5 million, or a net loss per basic and diluted share of $0.78, for the three months ended December 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526097582/0001193125-26-097582-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2025"},{"label":"Net income","value":"net loss of approximately $20.6 million, or a net loss per basic and diluted share of $1.25"},{"label":"EPS","value":"net loss per basic and diluted share of $1.25"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}